Study To Investigate Patient Preference On Dosing In Ibandronate And Risedronate In Korean Women With Postmenopausal Osteoporosis - Full Text View

Sponsored by:	GlaxoSmithKline
Information provided by:	GlaxoSmithKline
ClinicalTrials.gov Identifier:	NCT00405392

Purpose

This is a randomized open label, multi-centre study for Korean women with postmenopausal osteoporosis, evaluating the preference for either the once-monthly dosing of ibandronate or the once-weekly dosing of risedronate.

Eligible subjects will be randomised either ibandronate monthly regimen or risedronate weekly regimen.

Treatment period consists of 3 month with ibandronate 150mg and additional 12 week with risedronate 35 mg or vice versa.

After taking the first interventional medicine for 3 months or 12 weeks completely, a subject changes the treatment arm. There is no washout period.

Condition	Intervention	Phase
Postmenopausal Osteoporosis	Drug: Ibandronate (SB743830HD)	Phase IV

MedlinePlus related topics: Osteoporosis

Drug Information available for: Risedronate sodium Risedronic acid Ibandronate sodium Ibandronic acid

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Crossover Assignment, Efficacy Study
Official Title:	An Open-Label, Multi-Centre, Randomized Study to Investigate Patient Preference on Dosing in the Once-Monthly Ibandronate and the Once-Weekly Risedronate in Korean Women With Postmenopausal Osteoporosis. A Six-Month, Two-Sequence, and Two Period Crossover Study

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:

Proportion(%) of patients who prefer the once-monthly dosing of ibandronate to the once-weekly dosing of risedronate.

Secondary Outcome Measures:

Percentage of patients who think once-monthly ibandronate dosing is more convenient vs once-weekly risedronate dosing Mean percent change of serum CTx from baseline to visit3 for once-monthly dosing of ibandronate & once-weekly dosing of risedronate

Estimated Enrollment:	364
Study Start Date:	March 2007
Study Completion Date:	May 2008
Primary Completion Date:	May 2008 (Final data collection date for primary outcome measure)

Eligibility

Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Women with postmenopausal osteoporosis diagnosed by DXA scanning, defined by T-score of -2.5 SD at spine or femur.
Patients who have never received bisphosphonates therapy (bisphosphonates naive)

Exclusion Criteria:

Inability to stand or sit in the upright position for at least 60 minutes;
Hypersensitivity to any component of risedronate and ibandronate;
Administration of any investigational drug within 30 days preceding the first dose of the study drug;
Patient has been on hormone (estrogen) replacement therapy or other osteoporosis medication (e.g. SERMS and calcitonin) within the previous 3 months.
Patient has been on systemic corticosteroids therapy for more than 1 month within the past year.
Other bone disease except osteoporosis
Current medical history of uncontrolled major upper GI disease

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00405392

Sponsors and Collaborators

GlaxoSmithKline

Investigators

Study Director:

GSK Clinical Trials, MD, PhD

GlaxoSmithKline

More Information

Responsible Party:	GSK ( Study Director )
Study ID Numbers:	109393, ML20293
Study First Received:	November 29, 2006
Last Updated:	October 27, 2008
ClinicalTrials.gov Identifier:	NCT00405392
Health Authority:	Korea: Food and Drug Administration

Keywords provided by GlaxoSmithKline:

Ibandronate
risedronate
Osteoporosis
preference

Study placed in the following topic categories:

Calcium, Dietary
Ibandronic acid
Musculoskeletal Diseases
Osteoporosis, Postmenopausal

Osteoporosis
Bone Diseases, Metabolic
Bone Diseases
Risedronic acid

Additional relevant MeSH terms:

Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Therapeutic Uses
Physiological Effects of Drugs

Calcium Channel Blockers
Bone Density Conservation Agents
Cardiovascular Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 14, 2009